Patents by Inventor Yoshiyasu Aoki
Yoshiyasu Aoki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080260687Abstract: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent.Type: ApplicationFiled: April 16, 2008Publication date: October 23, 2008Inventors: Yoshiyasu Aoki, Giovanna Tosato
-
Patent number: 7374756Abstract: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent.Type: GrantFiled: May 14, 2007Date of Patent: May 20, 2008Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Yoshiyasu Aoki, Giovanna Tosato
-
Publication number: 20070243162Abstract: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent.Type: ApplicationFiled: May 14, 2007Publication date: October 18, 2007Inventors: Yoshiyasu Aoki, Giovanna Tosato
-
Patent number: 7235365Abstract: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent.Type: GrantFiled: July 25, 2006Date of Patent: June 26, 2007Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Yoshiyasu Aoki, Giovanna Tosato
-
Publication number: 20070015197Abstract: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent.Type: ApplicationFiled: July 25, 2006Publication date: January 18, 2007Inventors: Yoshiyasu Aoki, Giovanna Tosato
-
Patent number: 7108981Abstract: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent.Type: GrantFiled: July 14, 2005Date of Patent: September 19, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Yoshiyasu Aoki, Giovanna Tosato
-
Publication number: 20060039927Abstract: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent.Type: ApplicationFiled: July 14, 2005Publication date: February 23, 2006Inventors: Yoshiyasu Aoki, Giovanna Tosato
-
Patent number: 6939547Abstract: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent.Type: GrantFiled: July 31, 2001Date of Patent: September 6, 2005Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Yoshiyasu Aoki, Giovanna Tosato
-
Publication number: 20030211468Abstract: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSRV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSRV-associated disorder. The method for effectiveness the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to receptor component in the absence of the agent.Type: ApplicationFiled: January 14, 2003Publication date: November 13, 2003Inventors: Yoshiyasu Aoki, Giovanna Tosato
-
Patent number: 4767683Abstract: A non-aqueous electrochemical cell has an anode consisting of an element selected from the group consisting of lithium, sodium and aluminum; a cathode consisting of a porous carbon body and a current collector; and an electrolyte containing an oxyhalide, wherein the porous carbon body contains a carbon black having a structure wherein a thin layer of graphite crystals is formed on a surface of each of chain-like carbon black particles. The cell has a high discharge capacity and an excellent discharge efficiency in high rate discharge.Type: GrantFiled: December 7, 1987Date of Patent: August 30, 1988Assignees: Tokyo Shibaura Denki Kabushiki Kaisha, Toshiba Battery Co., Ltd.Inventors: Shuji Yamada, Takahisa Ohsaki, Kiyoshi Mitsuyasu, Yuichi Sato, Yoshiyasu Aoki, Kazuya Hiratsuka
-
Patent number: 4702977Abstract: There is disclosed a secondary battery using a non-aqueous solvent which comprises using a carbonaceous material obtained by carbonating an organic compound and having a pseudographite structure of a hydrogen/carbon ratio being 0.15 or less, a d.sub.002 being 3.37 .ANG. or more and a Lc being 150 .ANG. or less as a negative electrode.The battery has a large electric density, less in self-discharging and excellent in preservability.Type: GrantFiled: April 24, 1986Date of Patent: October 27, 1987Assignees: Toshiba Battery Co., Ltd., Mitsubishi Petrochemical Co., Ltd.Inventors: Kazuya Hiratsuka, Yuichi Sato, Yoshiyasu Aoki, Hiroshi Yui, Mitsutaka Miyabayashi, Akira Itsubo